MMP inhibitors project: open for out-licensing or co-development partnership
MMP-s are involved in acute ischemia/reperfusion injury. Inhibition of MMP-2 is able to reduce ishcemia/reperfusion injury, e.g. it can reduce infarct size (Giricz et al, J Pharm Exp Ther, 316:154-161, 2006)
Novel chemical entities (small molecules) for selective inhibition of MMP 2, 9, 13, and their application for ischemic (e.g. heart) diseases, or any other diseases where pathological increase in MMP activation is involved in the pathology.
Patented technology (primary filing date Dec, 2010, WO_2012/080762_A1)